Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Blood (2023) 142 (Supplement 1): 2952.

https://doi.org/10.1182/blood-2023-186514

Published: 2023

Journal Articles

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia, Lina Han, Cassandra L Ramage, Connie C. Weng, Lei Yang, Simona Colla, Helen Ma, Weiguo Zhang, Michael Andreeff, Naval Daver, Nitin Jain, Naveen Pemmaraju, Kapil N. Bhalla, Satu Mustjoki, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Qi Zhang, Marina Konopleva

Blood (2022) 140 (Supplement 1): 3347–3349.

https://doi.org/10.1182/blood-2022-164541

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

Qi Zhang, PhD, Lina Han, PhD, Alessia Lodi, PhD, Connie Weng, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Helen Ma, MS, Abhishek Maiti, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-142547

Published: 2020

Journal Articles

The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Xiyuan Lu, Alessia Lodi, PhD, Lina Han, PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD, Stefano Tiziani, PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141986

Published: 2020

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Lina Han, PhD, Antonio Cavazos, Natalia Baran, PhDMD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Joseph R Marszalek, PhD, Michael Andreeff, MD PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 5161.

https://doi.org/10.1182/blood-2019-124475

Published: 2019

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1369.

https://doi.org/10.1182/blood-2019-128618

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse

Lina Han, PhD, Peng Qiu, PhD, Jeffrey L. Jorgensen, MD PhD, Duncan Mak, BSc, MPhil, Jared K Burks, PhD, Teresa McQueen, MS, Zhihong Zeng, MD, Farhad Ravandi, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Steven M. Kornblau, MD, Michael Andreeff, MD PhD, Monica L. Guzman, PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 912.

https://doi.org/10.1182/blood-2018-99-111970

Published: 2018

Journal Articles

Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Tamar Uziel, PhD, Qi Zhang, PhD, Lina Han, PhD, Antonio Cavazos, MSc, Yu Shen, Marina Y. Konopleva, MD PhD, Xiaoyu Lin, Xin Lu, Lu Zhang

Blood (2018) 132 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2018-99-116912

Published: 2018

Journal Articles

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang, PhD, Tianyu Cai, PhD, Lina Han, PhD, Vinitha Mary Kuruvilla, Sharlene Adams, PhD, Sloss M Callum, Karine Harutyunyan, PhD, Andrew A. Lane, MD PhD, Yelena Kovtun, PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Patrick Zweider McKay, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2018-99-116771

Published: 2018

Journal Articles

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

Antonio Cavazos, MSc, Helen Ma, MS, Lina Han, PhD, Tianyu Cai, PhD, Qi Zhang, PhD MD, Karine Harutyunyan, PhD, Natalia Baran, PhD MD, Weiguo Zhang, MD PhD, Naval Daver, MD, Michael Andreeff, MD PhD, Amir Ashoorzadeth, PhD, Robert Anderson, MSc, PhD FNZIC, CChem, FRSC, Adam Patterson, PhD, Jeffrey B Smaill, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1342.

https://doi.org/10.1182/blood.V130.Suppl_1.1342.1342

Published: 2017

Journal Articles

Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models

Blood (2017) 130 (Supplement 1): 1350.

https://doi.org/10.1182/blood.V130.Suppl_1.1350.1350

Published: 2017

Journal Articles

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Qi Zhang, PhD MD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Antonio Cavazos, MSc, Helen Ma, MS, Venkata Lokesh Battula, PhD, Natalia Baran, PhD MD, Karine Harutyunyan, PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1362.

https://doi.org/10.1182/blood.V130.Suppl_1.1362.1362

Published: 2017

Journal Articles

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

Blood (2017) 130 (Supplement 1): 1322.

https://doi.org/10.1182/blood.V130.Suppl_1.1322.1322

Published: 2017

Journal Articles

Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759

Lina Han, PhD, Antonio Cavazos, MSc, Natalia Baran, PhD MD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 2623.

https://doi.org/10.1182/blood.V130.Suppl_1.2623.2623

Published: 2017

Journal Articles

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MSc, Lina Han, PhD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Sergej Naumovich Konoplev, MD PhD, Sattva S. Neelapu, MD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 2625.

https://doi.org/10.1182/blood.V130.Suppl_1.2625.2625

Published: 2017

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

NARROW

Minimal Residual Disease in Acute Myeloid Leukemia Following Induction Chemotherapy Can be Effectively Eradicated By Targeting Mitochondrial Metabolism

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Single-Cell Mass Cytometry Characterizes Phenotypic and Functional Heterogeneity in Acute Myeloid Leukemia at Diagnosis, in Remission and Relapse

Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Ruxolitinib or Dasatinib in Combination with Chemotherapy for Patients with Relapsed/Refractory Philadelphia (Ph)-like Acute Lymphoblastic Leukemia: A Phase I-II Trial

Targeting Residual Chemotherapy-Resistant Acute Myeloid Leukemia Cells By a Novel Oxphos Inhibitor IACS010759

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only